Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Overexpression of matrix metalloproteinase-7 and -9 in NSCLC tumor and stromal cells: correlation with a favorable clinical outcome.

Stenvold H, Donnem T, Andersen S, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM.

Lung Cancer. 2012 Feb;75(2):235-41. doi: 10.1016/j.lungcan.2011.06.010. Epub 2011 Jul 18.

PMID:
21764478
2.

Expression and clinical significance of matrix metalloproteinase (MMP)-26 protein in non-small cell lung cancer.

Li L, Mei TH, Zhou XD, Zhang XG.

Ai Zheng. 2009 Jan;28(1):60-3. Epub 2009 Jan 16.

PMID:
19448419
3.

Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small-cell lung cancer.

Suzuki M, Iizasa T, Fujisawa T, Baba M, Yamaguchi Y, Kimura H, Suzuki H.

Invasion Metastasis. 1998-1999;18(3):134-41.

PMID:
10474026
4.

[Prognostic impact of matrix metalloproteinases 2,9, and 11 in stromal cells stage I non-small cell lung cancer].

Drác P, Klein J, Tichý T, Kolek V, Skarda J.

Cas Lek Cesk. 2007;146(1):45-7. Czech.

PMID:
17310584
5.
6.

Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer.

Shao W, Wang W, Xiong XG, Cao C, Yan TD, Chen G, Chen H, Yin W, Liu J, Gu Y, Mo M, He J.

J Surg Oncol. 2011 Dec;104(7):841-6. doi: 10.1002/jso.22001. Epub 2011 Jun 30.

PMID:
21721010
7.

Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer.

Donnem T, Al-Saad S, Al-Shibli K, Delghandi MP, Persson M, Nilsen MN, Busund LT, Bremnes RM.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6649-57.

8.

The prognostic value of intraepithelial and stromal CD3-, CD117- and CD138-positive cells in non-small cell lung carcinoma.

Al-Shibli K, Al-Saad S, Andersen S, Donnem T, Bremnes RM, Busund LT.

APMIS. 2010 May;118(5):371-82. doi: 10.1111/j.1600-0463.2010.02609.x.

PMID:
20477813
9.

Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients.

Iizasa T, Fujisawa T, Suzuki M, Motohashi S, Yasufuku K, Yasukawa T, Baba M, Shiba M.

Clin Cancer Res. 1999 Jan;5(1):149-53.

10.

Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer.

Byun JH, Lee MA, Roh SY, Shim BY, Hong SH, Ko YH, Ko SJ, Woo IS, Kang JH, Hong YS, Lee KS, Lee AW, Park GS, Lee KY.

Jpn J Clin Oncol. 2006 May;36(5):263-8. Epub 2006 May 30.

PMID:
16735371
11.

Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas.

Yamamura T, Nakanishi K, Hiroi S, Kumaki F, Sato H, Aida S, Kawai T.

Lung Cancer. 2002 Mar;35(3):249-55.

PMID:
11844598
12.

The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer.

Al-Saad S, Al-Shibli K, Donnem T, Persson M, Bremnes RM, Busund LT.

Br J Cancer. 2008 Nov 4;99(9):1476-83. doi: 10.1038/sj.bjc.6604713. Epub 2008 Oct 14.

13.

Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.

Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM.

Clin Cancer Res. 2004 Nov 15;10(22):7621-8.

14.

VEGF-A and VEGFR-3 correlate with nodal status in operable non-small cell lung cancer: inverse correlation between expression in tumor and stromal cells.

Donnem T, Al-Shibli K, Al-Saad S, Delghandi MP, Busund LT, Bremnes RM.

Lung Cancer. 2009 Feb;63(2):277-83. doi: 10.1016/j.lungcan.2008.05.022. Epub 2008 Jul 2.

PMID:
18599153
15.

Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.

Schwandner O, Schlamp A, Broll R, Bruch HP.

Int J Colorectal Dis. 2007 Feb;22(2):127-36. Epub 2006 Aug 2.

PMID:
16896992
16.

Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.

Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT.

Clin Cancer Res. 2008 Aug 15;14(16):5220-7. doi: 10.1158/1078-0432.CCR-08-0133.

17.

Stage and tissue-specific prognostic impact of miR-182 in NSCLC.

Stenvold H, Donnem T, Andersen S, Al-Saad S, Busund LT, Bremnes RM.

BMC Cancer. 2014 Feb 27;14:138. doi: 10.1186/1471-2407-14-138.

18.

Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.

Gouyer V, Conti M, Devos P, Zerimech F, Copin MC, Créme E, Wurtz A, Porte H, Huet G.

Cancer. 2005 Apr 15;103(8):1676-84.

19.

Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer.

Liu H, Zhang T, Li X, Huang J, Wu B, Huang X, Zhou Y, Zhu J, Hou J.

Cancer Sci. 2008 Nov;99(11):2185-92. doi: 10.1111/j.1349-7006.2008.00922.x. Epub 2008 Sep 23.

20.

Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy.

Pritchard SC, Nicolson MC, Lloret C, McKay JA, Ross VG, Kerr KM, Murray GI, McLeod HL.

Oncol Rep. 2001 Mar-Apr;8(2):421-4.

PMID:
11182067

Supplemental Content

Support Center